

Literatur: Prof. Dr. med. R. Kimmig

1. Rachner TD, Kasimir-Bauer S, Göbel A, Erdmann K, Hoffmann O, Browne AJ, Wimberger P, Rauner M, Hofbauer LC, **Kimmig R**, Bittner AK.
Prognostic value of RANKL/OPG serum levels and disseminated tumor cells in non-metastatic breast cancer.
Clin Cancer Res. 2018 Nov 13.
2. Kuhlmann JD, Chebouti I, **Kimmig R**, Buderath P, Reuter M, Puppel SH, Wimberger P, Kasimir-Bauer S.
Extracellular vesicle-associated miRNAs in ovarian cancer - design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance.
Clin Chem Lab Med. 2018 Nov 13.
3. Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, **Kimmig R**, Kommos S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.
What is the evidence for lymphadenectomy in presumed early ovarian cancer?
Arch Gynecol Obstet. 2018 Oct 29.
4. Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, **Kimmig R**, Letsch A, Reinhardt M, et al
Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.
Geburtshilfe Frauenheilkd. 2018 Oct;78(10):949-971
5. **Rainer Kimmig**
Robotic-Assisted Radical Hysterectomy as Compartmental Resection According to rTMMR and rPMMR
Hysterectomy (2018)
6. Köninger A, Enekwe A, Mach P, Andrikos D, Schmidt B, Frank M, Birdir C, **Kimmig R**, Gellhaus A, Dieplinger H.
Afamin: an early predictor of preeclampsia.
Arch Gynecol Obstet. 2018 Nov;298(5):1009-1016 ,
7. Köninger A, Kampmeier A, Schmidt B, Frank M, Strowitzki T, **Kimmig R**, Gellhaus A, Mach P.
Trends in anti-Müllerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndrome.
Reprod Biomed Online. 2018 Sep;37(3):367-374

8. Mach P, Nolte-Boenigk L, Droste L, Fox L, Frank M, Schmidt B, Herse F, Verlohren S, Wicherek L, Iannaccone A, Birdir C, Andrikos D, **Kimmig R**, Gellhaus A, Köninger A.
Soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia.
Am J Reprod Immunol. 2018 Sep;80(3):e12988
9. **Kimmig R**, Ind T.
Minimally invasive surgery for cervical cancer: consequences for treatment after LACC Study.
J Gynecol Oncol. 2018 Jul;29(4):e75.
10. Keup C, Mach P, Aktas B, Tewes M, Kolberg HC, Hauch S, Sprenger-Haussels M, **Kimmig R**, Kasimir-Bauer S.
RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients.
Clin Chem. 2018 Jul;64(7):1054-1062
11. Birdir C, Droste L, Fox L, Frank M, Fryze J, Enekwe A, Köninger A, **Kimmig R**, Schmidt B, Gellhaus A.
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.
Pregnancy Hypertens. 2018 Apr;12:124-128.
12. Köninger A, Mathan A, Mach P, Frank M, Schmidt B, Schleussner E, **Kimmig R**, Gellhaus A, Dieplinger H.
Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study.
Reprod Biol Endocrinol. 2018 Mar 27;16(1):30.
13. Sarabhai T, Tschischka A, Stebner V, Nensa F, Wetter A, **Kimmig R**, Forsting M, Herrmann K, Umutlu L, Grueneisen J.
Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results.
Clin Imaging. 2018 May - Jun;49:163-168.
14. Köninger A, Kampmeier A, Mach P, Schmidt B, Strowitzki T, **Kimmig R**, Gellhaus A.
Tight interplay in early pregnancy between follistatin and anti-mullerian hormone in women with polycystic ovarian syndrome (PCOS).
Arch Gynecol Obstet. 2018 May;297(5):1307-1316.
15. König L, Kasimir-Bauer S, Bittner AK, Hoffmann O, Wagner B, Santos Manvailer LF, **Kimmig R**, Horn PA, Rebmann V.
Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.
Oncoimmunology. 2017 Sep 27;7(1)
16. Rusch P, **Kimmig R**, Lecuru F, Persson J, Ponce J, Degueldre M, Verheijen R
The Society of European Robotic Gynaecological Surgery (SERGS) Pilot Curriculum for robot assisted gynecological surgery.
Arch Gynecol Obstet. 2017 Dec 13

17. Harter P, Hauke J, Heitz F, Reuss A, Kommos S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, **Kimmig R**, Kast K, Sehoul J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
PLoS One. 2017 Oct 20;12(10):
18. van Dam PA, Tomatis M, Marotti L, Heil J, Mansel RE, Rosselli Del Turco M, van Dam PJ, Casella D, Bassani LG, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, **Kimmig R**, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A; eusomaDB Working Group.
Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.
Eur J Cancer. 2017 Sep 4;85:15-22.
19. Bredemeier M, Edimiris P, Mach P, Kubista M, Sjöback R, Rohlova E, Kolostova K, Hauch S, Aktas B, Tewes M, **Kimmig R**, Kasimir-Bauer S.
Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer.
Clin Chem. 2017 Aug 3. pii: clinchem.2016.269605.
20. **Kimmig R**, Buderath P, Rusch P, Mach P, Aktas B.
Early ovarian cancer surgery with indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, pelvic part).
J Gynecol Oncol. 2017 Sep;28(5)
21. A. Köninger, A. Winter, P. Rusch, M. Heubner, P. Mach, **R. Kimmig**
Spätfolgen der Sectioentbindung: Narbendefekte und Plazentationsstörungen
Der Gynäkologe 2017;8, 02.
22. Chebouti I, Kasimir-Bauer S, Buderath P, Wimberger P, Hauch S, **Kimmig R**, Kuhlmann JD.
EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
Oncotarget. 2017 Jul 25;8(30)48820-48831
23. Mach P, Gellhaus A, Prager S, Moore T, Wennemuth G, **Kimmig R**, Köninger A, Singer BB.
Soluble CEACAM1 and CEACAM6 are differently expressed in blood serum of pregnant women during normal pregnancy.
Am J Reprod Immunol. 2017 Jun 8
24. Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, **Kimmig R**, Aktas B.
Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.
Mol Med Rep. 2017 May;15(5):2957-2968.
25. Köninger A, Schmidt B, Damaske D, Birdir C, Enekwe A, **Kimmig R**, Strowitzki T, Gellhaus A.
Follistatin during pregnancy and its potential role as an ovarian suppressing agent.
Eur J Obstet Gynecol Reprod Biol. 2017 May;212:150-154

26. **Kimmig R**, Buderath P, Mach P, Rusch P, Aktas B.
Surgical treatment of early ovarian cancer with compartmental resection of regional lymphatic network and indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, paraaortic part).
J Gynecol Oncol. 2017 May;28(3):e41.
27. **Kimmig R**, Buderath P, Rusch P, Aktas B.
Technique of ICG-guided Targeted Compartmental Pelvic Lymphadenectomy (TCL) combined with Pelvic Peritoneal Mesometrial Resection (PMMR) for locoregional control of endometrial cancer - A proposal.
Gynecol Oncol Rep. 2017 Apr 6;20:125-126
28. Chebouti I, Kuhlmann JD, Buderath P, Weber S, Wimberger P, Bokeloh Y, Hauch S, **Kimmig R**, Kasimir-Bauer S.
ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
Oncotarget. 2017 Apr 11;8(15):24303-24313.
29. **Kimmig R**, Rusch P, Buderath P, Aktas B.
Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation.
Gynecol Oncol Rep. 2017 Feb 9;20:22-23
30. **Kimmig R**, Buderath P, Rusch P, Aktas B.
Surgical anatomy of the ligamentous mesometrium and robotically assisted ICG-guided resection in cervical cancer.
Gynecol Oncol Rep. 2017 Jan 21;20:4.
31. Gan C, Bossart M, Piek J, Halaska M, Haidopoulos D, Zapardiel I, Grabowski JP, Kesic V, **Kimmig R**, Cibula D, Lambaudie E, Verheijen R, Manchanda R.
Robotic and Advanced Laparoscopic Surgical Training in European Gynecological Oncology Trainees.
Int J Gynecol Cancer. 2017 Feb;27(2):375-381.
32. Harter P, Sehouli J, Reuss A, Baumann K, Hanker L, **Kimmig R**, Schröder W, Burges A, Gropp-Meier M, Kurzeder C, Mahner S, Canzler U, Lück HJ, Meier W, Fehm T, du Bois A.
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynäkologische Onkologie Study Group (AGO-GYN 7).
Int J Gynecol Cancer. 2016 Nov;26(9):1636-1641.
33. Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, **Kimmig R**, Zeller T, Heubner M.
Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer.
Future Sci OA. 2016 Oct 12;2(4)
34. **Kimmig, R**.
Congress Report Robot Surgery Congress
Geburtshilfe und Frauenheilkunde 2016 Sep. 76:9, 933

- 35.** **Kimmig R**, Rusch P, Buderath P, Aktas B.
Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer.
Gynecol Oncol Rep. 2016 Sep 14;18:14
- 36.** Kuhlmann JD, Bankfalvi A, Schmid KW, Callies R, **Kimmig R**, Wimberger P, Siffert W, Bachmann HS.
Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.
BMC Cancer. 2016 Aug 9;16:618
- 37.** A. Köninger, P. Mach, **R. Kimmig**, E. Schleußner
Amnioninfektionssyndrom
Der Gynäkologe 2016, 8:563-568
- 38.** **R. Kimmig**, A. Köninger, I. Mylonas
Infektionen in der Schwangerschaft
Der Gynäkologe 2016, 8:562
- 39.** **R. Kimmig**, B. Aktas, P. Rusch, M. Heubner
ICG-gestützte Navigation bei der Chirurgie uteriner Malignome
Der Gynäkologe, 2016;49 5: 373-379
- 40.** Muallem MZ, Dimitrova D, Pietzner K, Richter R, Feldheiser A, Scharfe I, Schmeil I, Hösl TM, Mustea A, Wimberger P, Burges A, **Kimmig R**, Sehouli J.
Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology. A NOGGO-AGO* survey of 144 Gynecological Departments in Germany.
Anticancer Res. 2016 Aug;36(8):4227-32.
- 41.** Rusch P, Hoffmann O, Stickelmann AL, Böhmer S, Gätje R, Krüger KG, Niesert S, Schmidt A, **Kimmig R**.
Distant metastasis detected by routine staging in breast cancer patients participating in the national German screening programme: consequences for clinical practice.
Springerplus. 2016 Jul 7;5(1):1010
- 42.** I. Alkatout, N. Maas, J.H. Egberts K.P. Jünemann, J. Ackermann, **R. Kimmig**
Roboterchirurgie in der Gynäkologie – Status quo
Der Gynäkologe 2016: 49: 470-476
- 43.** **Kimmig R**, Aktas B, Buderath P, Heubner M.
Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system.
Gynecol Oncol Rep. 2016 Mar 19;16:24
- 44.** Mach P, Köninger A, Wicherek L, **Kimmig R**, Kasimir-Bauer S, Birdir C, Schmidt B, Gellhaus A.
Serum concentrations of soluble B7-H4 in early pregnancy are elevated in women with preterm premature rupture of fetal membranes.
Am J Reprod Immunol. 2016 Aug;76(2):149-54

45. Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, Wagner J, **Kimmig R**, Kasimir-Bauer S.
Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
Oncotarget. 2016 May 20.
46. Kasimir-Bauer S, Reiter K, Aktas B, Bittner AK, Weber S, Keller T, **Kimmig R**, Hoffmann O.
Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
Sci Rep. 2016 May 23;6:26355
47. Birdir C, Fryze J, Nießen S, Schmidt M, Köninger A, **Kimmig R**, Schmidt B, Gellhaus A.
Impact of maternal serum levels of Visfatin, AFP, PAPP-A, sFlt-1 and PlGF at 11-13 weeks gestation on small for gestational age births.
J Matern Fetal Neonatal Med. 2016 May 16:1-6
48. Hoffmann O, Stamatis GA, Bittner AK, Arnold G, Schnabel R, Krüger K, **Kimmig R**, Heubner M.
B3-lesions of the breast and cancer risk - an analysis of mammography screening patients.
Mol Clin Oncol. 2016 May;4(5):705-708.
49. Chebouti I, Blassl C, Wimberger P, Neubauer H, Fehm T, **Kimmig R**, Kasimir-Bauer S.
Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
Oncotarget. 2016 Apr 1.
50. Kasimir-Bauer S, Bittner AK, König L, Reiter, Keller, **Kimmig R**, Hoffmann, O.
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Breast Cancer Res. 2016 Feb 12;18(1):20.
51. Rezai M, Strauß S, **Kimmig R**, Kern P.
Risk-reducing, conservative mastectomy-analysis of surgical outcome and quality of life in 272 implant-based reconstructions using TiLoop(®) Bra versus autologous corial flaps.
Gland Surg. 2016 Feb;5(1):1-8.
52. König L, Kasimir-Bauer S, Hoffmann O, Bittner AK, Wagner B, Manvailer LF, Schramm S, Bankfalvi A, Giebel B, **Kimmig R**, Horn PA, Rebmann V.
The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.
Hum Immunol. 2016 Jan 12.
53. **Kimmig R**, Aktas B, Buderath P, Rusch P, Heubner M.
Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine-green (ICG).
J Surg Oncol. 2016 Apr;113(5):554-9.

54. Buderath P, **Kimmig R**.
Oncological outcomes of robotic-assisted radical hysterectomy.
Minerva Ginecol. 2016;68(1):43-8
55. Kern P, Kalisch A, von Minckwitz G, Pütter C, Kolberg HC, Pott D, Kurbacher C, Rezai M, **Kimmig R**.
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
J Chemother. 2016 1-8:
56. **Kimmig R**, Iannaccone A, Aktas B, Buderath P, Heubner M.
Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.
Arch Gynecol Obstet. 2015 Nov 23.
57. Rezai M, Kraemer S, **Kimmig R**, Kern P.
Breast conservative surgery and local recurrence.
Breast. 2015 Nov.;24 Suppl 2:S100-7
58. Kern P, VON Minckwitz G, Puetter C, Pavlidou S, Flach A, **Kimmig R**, Rezai M.
Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer.
Anticancer Res. 2015 Oct;35(10): 5479-84.
59. van Dam PA, Tomatis M, Marotti L, Heil J, Wilson R, Rosselli Del Turco M, Mayr C, Costa A, Danei M, Denk A, Emons G, Friedrichs K, Harbeck N, Kiechle M, Koheler U, Kuemmel S, Maass N, Marth C, Prové A, **Kimmig R**, Rageth C, Regolo L, Salehi L, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Ponti A; eusomaDB Working Group.; eusomaDB Working Group.
The effect of EUSOMA certification on quality of breast cancer care.
Eur J Surg Oncol. 2015 Oct;41(10):1423-9.
60. Köninger A, Schmidt B, Mach P, Damaske D, Nießen S, **Kimmig R**, Strowitzki T, Gellhaus A.
Anti-Mullerian-Hormone during pregnancy and peripartum using the new Beckman Coulter AMH Gen II Assay.
Reprod Biol Endocrinol. 2015 Aug 7;13:86;
61. Zola P, Macchi C, Cibula D, Colombo N, **Kimmig R**, Maggino T, Reed N, Kesic V.
Follow-up in Gynecological Malignancies: A State of Art.
Int J Gynecol Cancer. 2015 Sep;25(7):1151-64.
62. Kern P, Zarth F, **Kimmig R**, Rezai M.
Impact of Age, Obesity and Smoking on Patient Satisfaction with Breast Implant Surgery - A Unicentric Analysis of 318 Implant Reconstructions after Mastectomy.
Geburtshilfe Frauenheilkd. 2015 Jun;75(6):597-604.
63. P. Edimiris, **R. Kimmig**, A. Köninger
Bedeutung der Insulinresistenz beim polyzystischen Ovarsyndrom – prä- und postkonzeptionell
Der Gynäkologe 2015;48:903-908

64. Heubner M, Wimberger P, Kasimir-Bauer S, Singer BB, Ruf P, **Kimmig R**, Siffert W.
Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects.
Arch Gynecol Obstet. 2015 Dec;292(6):1367-72
65. Radtke, S., Gorgens, A., Kordelas, L., Schmidt, M., **Kimmig R**, Köninger, A., Horn P.A., Giebel, B.
CD133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants
BRITISH JOURNAL OF HAEMATOLOGY, Jun. 2015, 169 (6), 868-878
66. Bachmann HS, Meier W, du Bois A, **Kimmig R**, Kuhlmann JD, Siffert W, Sehoul J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P.
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Br J Clin Pharmacol. 2015 Nov;80(5):1139-48
67. Otto T, Gellhaus A, Lüschen N, Scheidler J, Bendix I, Dunk C, Wolf N, Lennartz K, Köninger A, Schmidt M, **Kimmig R**, Fandrey J, Winterhager E.
Oxygen Sensitivity of Placental Trophoblast Connexins 43 and 46: A Role in Preeclampsia?
J Cell Biochem. 2015 Dec;116(12):2924-37.
68. Rezai M, Kellersmann S, Knispel S, Lax H, **Kimmig R**, Kern P.
Translating the concept of intrinsic subtypes into an oncoplastic cohort of more than 1000 patients - predictors of recurrence and survival.
Breast. 2015 Aug;24(4):384-90.
69. Hoffmann O, Schroer-Zuendorf IA, Kasimir-Bauer S, Oberhoff C, **Kimmig R**, Heubner M.
Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
Arch Gynecol Obstet. 2015 Nov;292(5):1117-25
70. Birdir C, Janssen K, Stanescu AD, Enekwe A, Kasimir-Bauer S, Gellhaus A, **Kimmig R**, Köninger A.
Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia.
Arch Gynecol Obstet. 2015 Nov;292(5):1033-42.
71. Mach P, Gellhaus A, Wicherek L, Schmidt B, **Kimmig R**, Kasimir-Bauer S, Köninger A.
Changes in the Blood Serum Levels of the Costimulatory Soluble B7-H4 Molecule in Pregnant Women During the Peripartal Phase.
Am J Reprod Immunol. 2015 Sep;74(3):209-15
72. Rezai M, Knispel S, Kellersmann S, Lax H, **Kimmig R**, Kern P.
Systematization of Oncoplastic Surgery: Selection of Surgical Techniques and Patient-Reported Outcome in a Cohort of 1,035 Patients.
Ann Surg Oncol. 2015 Oct;22(11):3730-7.

73. Köninger A, Koch L, Enekwe A, Birdir C, Kasimir-Bauer S, **Kimmig R**, Strowitzki T, Schmidt B.
Change of anti-Mullerian-hormone levels during follicular phase in PCOS patients.
Gynecol Endocrinol 2015 Jan;31(1):26-30.
74. A, Iannaccone, A. Enekwe, A. Winter, **R. Kimmig**, A. Köninger
Geburtseinleitung: „anything new?“
Der Gynäkologe 2015;48:753-757
75. A. Enekwe, **R. Kimmig**, I. Bialas, A. Köninger
Substanzabusus in der Schwangerschaft
Der Gynäkologe 2015;48:464-469
76. C. Birdir, **R. Kimmig**, A. Köninger
Präeklampsiescreening im ersten Trimenon
Der Gynäkologe 2015;48:394-398
77. E. Edeler, A. Heubner, **R. Kimmig**, A. Köninger
Update Folsäurestoffwechsel
Der Gynäkologe 2015;48:159-163
78. Tewes M, Kasimir-Bauer S, Welt A, Schuler M, **Kimmig R**, Aktas B.
Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.
J Cancer Res Clin Oncol. 2015 Jan;141(1):87-92.
79. Söhngen L, Schmidt M, Wimberger P, **Kimmig R**, Grümmer R.
Additional B-cell deficiency does not affect growth and angiogenesis of ectopic human endometrium in T-cell-deficient endometriosis mouse models during long-term culture.
J Reprod Immunol. 2014 Dec;106:50-7.
80. du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, **Kimmig R**, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P.
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
J Clin Oncol. 2014 Oct 20;32(30):3374-82.
81. **Kimmig, R.**
Innovationen in der operativen Therapie von Genitalkarzinomen
Der Gynäkologe, 2014 12;932-941
82. **R. Kimmig**, B. Aktas, M. Heubner
“Robotioc surgery” in der Gynäkologie
Der Gynäkologe 2014;47:184-190
83. Köninger A, Koch L, Edimiris P, Nießen S, Kasimir-Bauer S, **Kimmig R**, Strowitzki T, Schmidt B.
Intraindividual right-left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis.
Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:124-9.

84. Aktas, B. Hoffmann, O., **Kimmig R.**
Die junge Mammakarzinom-Patientin: Was ist zu beachten?
Ärztliches Journal Onkologie 2014;5:20-25
85. Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, **Kimmig R**, Kasimir-Bauer S.
ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance.
Clin Chem. 2014 Oct;60(10):1282-9.
86. Köninger A, Koch L, Edimiris P, Enekwe A, Nagarajah J, Kasimir-Bauer S, **Kimmig R**, Strowitzki T, Schmidt B.
Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome.
Arch Gynecol Obstet. 2014 Nov;290(5):1023-30.
87. Heubner M, **Kimmig R**, Aktas B, Siffert W, Frey UH
The haplotype of three polymorphisms in the *SATB1* promoter region impacts survival in breast cancer patients..
Oncol Lett. 2014 Jun;7(6):2007-2012. 2014 Mar 20.
88. Köninger A, Edimiris P, Koch L, Enekwe A, Lamina C, Kasimir-Bauer S, **Kimmig R**, Dieplinger H.
Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome.
Endocr Connect. 2014 Sep;3(3):120-6.
89. Wimberger P, Chebouti I, Kasimir-Bauer S, Lachmann R, Kuhlisch E, **Kimmig R**, Süleyman E, Kuhlmann JD.
Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
Gynecol Oncol. 2014 Jun;133(3):467-72
90. Köninger A, Sauter L, Edimiris P, Kasimir-Bauer S, **Kimmig R**, Strowitzki T, Schmidt B.
Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome.
Hum Reprod. 2014 Mar;29(3):518-24.
91. **R. Kimmig**, N. Maass
Laparoskopie in der gynäkologischen Onkologie
Der Gynäkologe 2014 März: 47, 3: 165-166
92. **R. Kimmig**, N. Maass
Laparoskopie und roboterassistierte Chirurgie in der Gynäkologie
Der Gynäkologe 2014 März: 47, 3: 164
93. Kuhlmann JD, Baraniskin A, Hahn SA, Mosel F, Bredemeier M, Wimberger P, **Kimmig R**, Kasimir-Bauer S.
Circulating u2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.
Clin Chem. 2014 Jan;60(1):206-13

94. Heitz F, Amant F, Fotopoulou C, Battista MJ, Wimberger P, Traut A, Fisseler-Eckhoff A, Harter P, Vandenput I, Sehouli J, Schmidt M, **Kimmig R**, du Bois R, du Bois A.
Synchronous ovarian and endometrial cancer-an international multicenter case-control study.
Int J Gynecol Cancer. 2014 Jan;24(1):54-60.
95. Köninger A, Sauter L, Edimiris P, Kasimir-Bauer S, **Kimmig R**, Strowitzki T, Schmidt B.
Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome.
Hum Reprod. 2014;29(3):518-24
96. Aktas B, Bankfalvi A, Heubner M, **Kimmig R**, Kasimir-Bauer S.
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Mol Clin Oncol. 2013 Nov;1(6):1049-1054
97. Kern P, Kalisch A, Kolberg HC, **Kimmig R**, Otterbach F, von Minckwitz G, Sikov WM, Pott D, Kurbacher C.
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response
Chemotherapy. 2013;59(5):387-94.
98. Welt A, Tewes M, Aktas B, Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, **Kimmig R**, Schuler M, Kasper S.
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Breast Cancer Res Treat. 2013;142(1):81-88
99. Kimmig, R., Buderath, P., Aktas, B., Heubner, M.
Peritoneale mesometriale Resektion (PMMR als Kompartiment-basierte Operation)
Der Gynäkologe 2013 Oct.: 751-56
100. Harter P, Sehouli J, **Kimmig R**, Rau J, Hilpert F, Kurzeder C, Elser G, du Bois A.
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Invest New Drugs. 2013;31(6):1499-504
101. **Kimmig R**, Aktas B, Buderath P, Wimberger P, Iannaccone A, Heubner M.
Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Hockel translated to robotic surgery.
World J Surg Oncol. 2013 Aug 16;11(1):198.

102. **Kimmig R**, Wimberger P, Buderath P, Aktas B, Iannaccone A, Heubner M. Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as 'total mesometrial resection (TMMR)' by Michael Hockel translated to robotic surgery (rTMMR). *World J Surg Oncol.* 2013 Aug 26;11(1):211.
103. **R. Kimmig**, B. Aktas, M. Heubner
Endometriumkarzinom - operative Strategie und Adjuvant
Der Gynäkologe 2013;Mai,339-344
104. Köninger A, Kauth A, Schmidt B, Schmidt M, Yerlikaya G, Kasimir-Bauer S, **Kimmig R**, Birdir C.
Anti-Müllerian-hormone levels during pregnancy and postpartum.
Reprod Biol Endocrinol. 2013 Jul 11;11(1):60
105. Aktas B, Kasimir-Bauer S, Lehmann N, **Kimmig R**, Tewes M.
Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Oncol Rep. 2013 Jul;30(1):441-7.
106. Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, **Kimmig R**, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S.
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
Int J Gynecol Cancer. 2013 Jun;23(5):839-45
107. Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F; **Kimmig R.**, ESGO 'Cancer in Pregnancy' Task Force.
Cancer in pregnancy: a survey of current clinical practice.
Eur J Obstet Gynecol Reprod Biol. 2013;167(1): 18-23 Mar.
108. **Kimmig R.**, Iannaccone, A., Buderath P, Aktas B., Wimberger P., Heubner M.
Definition of Compartment Based Radical Surgery in Uterine Cancer-Part I: Therapeutic Pelvic and Periaortic Lymphadenectomy by Michael Höckel Translated to Robotic Surgery
*ISRN Obstet Gynecol.*2013;2013:297921 *Clinical Study* 2013 Jan.; 19
109. Aktas B, Kasimir-Bauer S, Wimberger P, **Kimmig R**, Heubner M.
Utility of Mesothelin, L1CAM and Afamin as Biomarkers in Primary Ovarian Cancer.
Anticancer Res. 2013 Jan;33(1):329-36.
110. Steiner, E, Juhasz-Bosz, I, Emons, G. **Kimmig R**, Mallmann P
Transvaginal Ultrasound for Endometrial Carcinoma Screening - Current Evidence-based Data.
Geburtshilfe Frauenheilkd. 2012;72(12): 1088-1091
111. Gottschalk N, **Kimmig R**, Lang S, Singh M, Brandau S.
Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity.
Int J Mol Sci. 2012;13(9):12000-16.
112. Kasimir-Bauer, S., Wimberger P., **Kimmig R.**
Schlafende Tumorzellen - Widerstandskämpfer der gynäkologischen Tumorerkrankungen
UNIKATE 11;2012:81-89

113. Mikat B, Gellhaus A, Wagner N, Birdir C, **Kimmig R**, Köninger A.
Early detection of maternal risk for preeclampsia.
Obstet Gynecol. 2012;2012:172808.
114. Riegger C, Koeninger A, Hartung V, Otterbach F, **Kimmig R**, Forsting M, Bockisch A, Antoch G, Heusner TA.
Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
Acta Radiol. 2012 Dec 1;53(10):1092-8.
115. Gottschalk N, Lang S, **Kimmig R**, Singh M, Brandau S.
Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
BMC Cancer. 2012 Oct 4;12(1):451.
116. Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, **Kimmig R**, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, Turco MR, Ponti A; Eusoma DB Working Group.
Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database.
Eur J Cancer. 2012 Sep. 48 (13):1947-56.
117. Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, **Kimmig R**, Kasimir-Bauer S.
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.
BMC Cancer. 2012 Jul 31;12(1):325.
118. **R. Kimmig**
„Robotic surgery beim Zervixkarzinom“
Gynäkologe 2012;45:707-713
119. Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, Dubois A, Olbrich C, Simon E, Friese K, **Kimmig R**, Boehmer D, Lichtenegger W, Kuemmel, S.
A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.
Ann Oncol. 2012 Sep.;23(9):2259-64
120. Buchbender C, Kuemmel S, Hoffmann O, Stahl AR, **Kimmig R**, Otterbach F, Ladd S, Koeninger A, Forsting M, Bockisch A, Antoch G, Heusner TA.
FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Acta Radiol. 2012 Jul 1;53(6):628-36. 2012 Jul 3.
121. M. Heubner, **R. Kimmig**
Hormonaktive Ovarialtumoren
Der Gynäkologe 2012;45:352-354

122. Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, **Kimmig R**, Forsting M, Antoch G, Heusner TA.
Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Acta Radiol. 2012 Jun 1;53(5):518-23. 2012 Apr 30.
123. Kasimir-Bauer S, Hoffmann O, Wallwiener D, **Kimmig R**, Fehm T.
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Breast Cancer Res. 2012 Jan 20;14(1):R15.
124. Soliman AA, Heubner M, **Kimmig R**, Wimberger P.
Morbidity of inguinofemoral lymphadenectomy in vulval cancer.
ScientificWorldJournal. 2012;2012:341253
125. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, **Kimmig R**, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.
A phase 3 trial of bevacizumab in ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2484-96. Erratum in: *N Engl J Med.* 2012 Jan 19;366(3):284.
126. **R. Kimmig**
Robotic Surgery in der Gynäkologie- Chirurgie der Zukunft oder teurer PR-Gag?
Der Gynäkologe 2011;44:401-404
127. van der Zee AG, Colombo N, Gitsch G, Reed N, Amant F, Cibula D, Kesic VI, **Kimmig R**, Lopes AD, Markowska J, Marth C, Radolakis A, Salvesen H, Vaitkiene D, Verheijen RH, Zola P.
ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
Int J Gynecol Cancer. 2012 Jan;22(1):175.
128. Verheijen RH, Cibula D, Zola P, Reed N; council of the European Society of Gynaecologic Oncology,
Cancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statement.
Int J Gynecol Cancer. 2012 Jan;22(1):170-4.
129. Mikat B, Zeller A, Scherag A, Drommelschmidt K, **Kimmig R**, Schmidt M.
βhCG and PAPP-A in First Trimester: Predictive Factors for Preeclampsia?
Hypertens Pregnancy. 2011;31(2): 261-7
130. Sismondi P, **Kimmig R**, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P.
Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients-Data from LIBERATE trial.
Maturitas. 2011 Dec;70(4):365-72.
131. Hoffmann O, Aktas B, Goldnau C, Heubner M, Oberhoff C, **Kimmig R**, Kasimir-Bauer S.
Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.

Anticancer Res. 2011 Oct;31(10):3623-8.

- 132.** Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, **Kimmig R**, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.
Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study.
J Clin Oncol. 2011 Oct 1;29(28):3791-7.
- 133.** A. Königer, **R. Kimmig**
Geschichte der operative Gynäkologie am Beispiel der Hysterektomie – eine Zeitreise
Der Gynäkologe
- 134.** Yang W, Wagener J, Wolf N, Schmidt M, **Kimmig R**, Winterhager E, Gellhaus
Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3.
Hum Reprod. 2011 Oct;26(10):2850-60.
- 135.** Aktas B, Kasimir-Bauer S, Heubner M, **Kimmig R**, Wimberger P.
Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.
Int J Gynecol Cancer. 2011 Jul;21(5):822-30.
- 136.** Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer S, **Kimmig R**, Wohlschlaeger J, Sixt SU.
Circulating 20S Proteasome in Patients with Non-metastasized Breast Cancer.
Anticancer Res. 2011 Jun;31(6):2197-201.
- 137.** Sauerwein W, Hoffmann O., Schütte, M., Aktas B., Abu Jawad J., Stuschke, M. **Kimmig R.**
Intraoperative Irradiation of the Tumor bed as a Boost in the Burst-sustaining Primary treatment of Breast cancer - Initial results and issues that arises
Strahlentherapie und Onkologie 2011;187 (Suppl. 1):99-100.
- 138.** Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, Gitsch G, Kesic V, **Kimmig R**, Markowska J, Marth C, Reed N, Rodolakis A, Salvesen H, Vaitkiene D, van der Zee AG, Zola P.
Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology: European Society of Gynecological Oncology (ESGO) Statement.
Int J Gynecol Cancer. 2011 Jun 28.
- 139.** Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, **Kimmig R**, Kasimir-Bauer S.
Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.
Genes Chromosomes Cancer. 2011 Aug;50(8):598-605.
- 140.** Erim Y, Beckmann M, Hoffmann O, Wimberger, P., **Kimmig, R.**
Predictors of Psychological Stress in Breast Cancer Patients - What Should Physicians and Nursing Staff Pay Attention to in an Oncological Setting?
Geburtshilfe und Frauenheilkunde 2011 Apr.2011; 71 (4), 285-291.

141. **Kimmig in:** Janni W., Maass, N.
 Robotic Surgery in der Gynäkologie – Chirurgie der Zukunft oder teurer PR-Gag?
Der Gynäkologe 5/2011; 401-404
142. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, **Kimmig R**, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; on behalf of Gynecologic Cancer Intergroup.
 Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIg) CALYPSO sub-study.
Ann Oncol. 2011 Mar 14.
143. Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, **Kimmig R**, Wimberger P.
 EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Med Oncol. 2011 Jun;28(2):626-30. Epub 2010 Apr.
144. Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, **Kimmig R**, Schwarzenbach H.
 Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
Int J Cancer. 2011 Jun 1; 128(11):2572-80. 2010 Oct.
145. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, **Kimmig R**, Peters J, Wohlschlaeger J, Sixt SU.
 The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer.
Gynecol Oncol. 2011 Feb;120(2):233-8.
146. Goldnau C., Köninger A, **Kimmig R**.
 [The female external genitalia: Pathologic findings and first steps in treatment.]
Urologe A. 2010 Dec;49(12):1496-502.
147. Mensah J, **Kimmig R**, Schmidt M.
 Ovarian Hyperstimulation Syndrome in an Aneuploid Pregnancy
Geburtshilfe und Frauenheilkunde 2010 Oct.; 70 (10): 828-831
148. Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA, Antoch G, Bockisch A, **Kimmig R**, Schmid KW, Stahl AR.
 The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer.
J Nucl Med. 2010 Aug;51(8):1191-7.
149. Hauth E, Umutlu L, Kümmel S, **Kimmig R**. et al
 Follow-up of Probably Benign Lesions (BI-RADS 3 category) in Breast MR Imaging
Breast Journal 2010 May-Jun;16(3) 297-304
150. Landt S, Sina F, **Kimmig R**, Schmidt M.
 [H1N1--pregnancy as risk factor]
Z Geburtshilfe Neonatol. 2010 Apr;214(2):48-51. 2010 Apr 21. German.
151. Barbara Mikat, **Rainer Kimmig**, Markus Schmidt
 Diagnostik und Therapie der Präeklampsie – State of the Art
Gynäkologie

152. M.Stuschke, **R. Kimmig**
Risikoadaptierte Strahlentherapie bei brusterhaltender Therapie des frühen Mammakarzinoms
Der Gynäkologe 2010;43:10,848-852
153. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, **Kimmig R**, Siffert W.
The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
Oncol Res. 2010;18(7):343-7.
154. Wimberger P, Wehling M, Lehmann N, **Kimmig R**, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A.
Influence of Residual Tumor on Outcome in Ovarian Cancer Patients with FIGO Stage IV Disease: An Exploratory Analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Ann Surg Oncol. 2010 Jun;17(6):1642-8. 2010 Feb 18.
155. Otterbach F, Callies R, Adamzik M, **Kimmig R.**, Siffert W, Schmid KW, Bankfalvi A
Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas
BREAST CANCER RESEARCH AND TREATMENT 2010;120 (1):67-76
156. Tan S, Scherag A, Janssen OE, Hahn S, Lahner H, Dietz T, Scherag S, Grallert H, Vogel CI, **Kimmig R**, Illig T, Mann K, Hebebrand J, Hinney A.
Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS).
BMC Med Genet. 2010 Jan 21;11(1):12.
157. Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, **Kimmig R**, Nuckel H.
Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.
Int J Biol Markers. 2009 Oct-Dec;24(4):223-9.
158. Hoffmann O, Solomayer E, Kuemmel S, Hahn M, Kasimir-Bauer S.), **Kimmig R**, Wallwiener D, Fehm T.
Does Primary Systemic Therapy Eradicate Disseminated and Circulating Tumor Cells?
Cancer Research 2009;69 Suppl. 24: 647 S-647 S
159. Wimberger P. Schröder W. **Kimmig R.**
Epitheliales Ovarialkarzinom. Neue molekularbiologische Ansätze
Management des Ovarialkarzinoms Hrsg. Kreienberg et. Al
Springer Verlag 2009; S. 218-230;
160. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, **Kimmig R**, Forsting M, Bockisch A, Antoch G, Stahl A.
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1543-50.

161. P. Wimberger, P. Sevelde, **R. Kimmig**
Schwangerschaftsbedingte Trophoblasttumoren
Die Onkologie 2. Auflage, Teil 2, 2009;1022 – 1037
162. Erim Y, Beckmann M, Gerlach G, Kümmel S, Oberhoff C, Senf W, **Kimmig R**.
[Screening for distress in women with breast cancer diagnosed for the first time:
employment of HADS-D and PO-Bado]
Z Psychosom Med Psychother. 2009;55(3):248-62. German.
163. Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, **Kimmig R**,
Kasimir-Bauer S.
Comparative evaluation of cell-free tumor DNA in blood and disseminated
tumor cells in bone marrow of patients with primary breast cancer.
Breast Cancer Res. 2009 Sep 21;11(5):R71.
164. P. Wimberger, **R. Kimmig**
Gynäkologische Malignome - Das Sentinelkonzept ist nicht immer geeignet
Info Onkologie 02/2009, S. 37 - 41
165. Mönckedieck V, Sannecke C, Husen B, Kumbartski M, **Kimmig R**, Tötsch M,
Winterhager E, Grümmer R.
Progestins inhibit expression of MMPs and of angiogenic factors in human
ectopic endometrial lesions in a mouse model.
Mol Hum Reprod. 2009 Oct;15(10):633-43. 2009 Aug 11.
166. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D,
Kimmig R, Kasimir-Bauer S.
Detection and characterization of circulating tumor cells in blood of primary
breast cancer patients by reverse-transcriptase polymerase chain reaction and
comparison to status of bone marrow disseminated cells.
Breast Cancer Res. 2009 Aug 10;11(4):R59.
167. Heubner M, Wimberger P, Kasimir-Bauer S, Otterbach F, **Kimmig R**, Siffert W.
The AA genotype of a L1C G842A polymorphism is associated with an
increased risk for ovarian cancer.
Anticancer Res. 2009 Aug;29(8):3449-52.
168. Untch M., Beckmann MW., Emons G., Thomssen Ch, **Kimmig R**
Tibolon erhöht das Rezidivrisiko bei Mammakarzinompatientinnen – neueste
Daten aus der LIBERATE-Studie.
Frauenheilkunde up2date 2009;3 (6) 168-172
169. Untch, M., Beckmann, MW, Emons, G., Thomssen C., **Kimmig R**.
The LIBERATE Study: Hormone Replacement Therapy with Tibolone Increases
the Risk of Recurrence and Metastases in Breast Cancer Patients
Geburtshilfe Frauenheilkd. 2009;69(3): 199-201
170. Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück
HJ, **Kimmig R**, Pfisterer J
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial
ovarian cancer and relapse within 12 months following 1st-line
platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by
the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study
Group (AGO-OVAR).
Gynecol Oncol. 2009 Aug;114(2):199-205.

171. Aktas B, Tewes M, Fehm T, Hauch S, **Kimmig R**, Kasimir-Bauer S.
Stem cell and epithelial-mesenchymal transition markers are frequently over-expressed in circulating tumor cells of metastatic breast cancer patients.
Breast Cancer Res. 2009 Jul 9;11(4):R46.
172. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, **Kimmig R**, Kasimir-Bauer S.
Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
Breast Cancer Res Treat. 2009 Jun;115(3):581-90.
173. Wimberger P, **Kimmig R**.
Significance of laparoscopy in gynaecological oncology: limitations for adnexal tumours
Gynakol Geburtshilfliche Rundsch. 2009;49(3):133-7.
174. Fink D, Lang U, **Kimmig R**.
Use of laparoscopy in gynecological oncology
Gynakol Geburtshilfliche Rundsch. 2009;49(3):109-10.
175. Schmidt M, Hoffmann B, **Kimmig R**, Kasimir-Bauer S.
mRNA of Placental Origin in Maternal Serum of Women with Normal and Preeclamptic Pregnancies.
Fetal Diagn Ther. 2009 Jun 11;25(2):269-276
176. Wimberger P, Heubner M, Lindhofer H, Jäger M, **Kimmig R**, Kasimir-Bauer S.
Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Anticancer Res. 2009 May;29(5):1787-91.
177. Emons G, **Kimmig R**.
Interdisciplinary S2k guidelines on the diagnosis and treatment of endometrial carcinoma.
J Cancer Res Clin Oncol. 2009 Oct;135(10):1387-91.
178. Schmidt M, Dogan C, Birdir C, Kuhn U, Gellhaus A, **Kimmig R**, Kasimir-Bauer S.
Placental growth factor: a predictive marker for preeclampsia?
Gynakol Geburtshilfliche Rundsch. 2009;49(2):94-9.
179. Imthurn B, **Kimmig R**, Lang U, Fink D.
New developments in reproductive medicine
Gynakol Geburtshilfliche Rundsch. 2009;49(2):53-4.
180. Hauth EA, Umutlu L, Libera H, **Kimmig R**, Forsting M.
Magnetic resonance imaging of the pelvis in patients with polycystic ovary syndrome
Rofo. 2009 Jun;181(6):543-8.
181. Schmidt M, Callies R, Kuhn U, Willruth A, **Kimmig R**.
External cephalic version in cases of breech presentation: renaissance of a well-known procedure?
Gynakol Geburtshilfliche Rundsch. 2009;49(1):29-34.
182. Lang U, Fink D, **Kimmig R**.
Intrauterine programming of specific organ systems]
Gynakol Geburtshilfliche Rundsch. 2009;49(1):1.

183. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; **LIBERATE Study Group**.
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Lancet Oncol. 2009 Feb;10(2):135-46.
184. Heubner M, Riemann K, Otterbach F, **Kimmig R**, Kasimir-Bauer S, Siffert W, Wimberger P.
The haplotype of two FSHR polymorphisms in ovarian cancer- A potential role of ethnology in risk modification.
Gynecol Oncol. 2009 Mar; 112 (3): 486-9.
185. B. Aktas, M. Tewes, S. Hauch, **R. Kimmig**, S. Kasimir-Bauer
Zirkulierende Tumorzellen beim metastasierten Mammakarzinom
Med Review 02/2009, S 3 - 4
186. Wimberger P, **Kimmig R**.
The role of radical lymphadenectomy: Experiences from the AGO Ovarian Cancer Study Group.
Urologe A. 2009 Jan; 48 (1):26-31.2008 Dec 7
187. M.W. Beckmann, G. Emons, **R. Kimmig**, P. Mallmann
AGO: Aktuelles aus S2 k-Leitlinien zur Diagnostik und Therapie des Endometriumkarzinoms und des Zervixkarzinoms
Forum 2 2008 Deutsche Krebsgesellschaft e. V.
188. Otterbach F, Callies R, **Kimmig R**, Schmid KW, Bánkfalvi A.
Aquaporin 1 expression in invasive breast carcinomas]
Pathologe. 2008 Nov;29 Suppl 2:357-62.
189. Lang U, Fink D, **Kimmig R**.
Fetal programming]
Gynakol Geburtshilfliche Rundsch. 2008;48(4):205-6.
190. Hilpert F, Harter P, Wimberger P, **Kimmig R**, Pfisterer J, du Bois A
Treatment of elderly patients with advanced ovarian cancer in the context of controlled clinical trials - A joint analysis of 3 AGO-Ovar subprojects
Geburtshilfe Frauenheilkd. 2008;68 Suppl. : S13-S13
191. Hauth EA, Umutlu L, Quinsten A, Kummel S, **Kimmig R**, Forsting M
MR-guided vacuum assisted breast biopsy with the ATEC (R) breast biopsy and excision system
Geburtshilfe Frauenheilkd. 2008;68(9): 901-906
192. Distler W, Beckmann MW, **Kimmig R**, Runnebaum I, Eiermann W
ATAC-Study: 100 months lasting analyze shows that after therapy ending considered effectiveness of Anastrozol versus Tamoxifen Carry-over-Effect benefits in adjustment of fractured rat in Arimidex, Tamoxifen, Alone or in Combination (ATAC)-Study
Geburtshilfe Frauenheilkd. 2008;68 Suppl. : S30-S30
193. Birdir C, Callies R, Schmidt M, Stein A, **Kimmig R**
Tuberculosis pericarditis constrictive in the pregnancy - A Case report
Geburtshilfe Frauenheilkd. 2008;68(3): 310-310

194. Wimberger, P, Welt A, **Kimmig R.**
Infertilität: Prophylaxe und Behandlung
Supportive Therapie in der Onkologie 2008 11/2008 463-475.
195. Nierwetberg D, Schmidt M, **Kimmig R.**
[Hormone replacement therapy and cancer risk]
MMW Fortschr Med. 2008 Oct 23;150(43):27-8.
196. Köninger A, Kümmel S, **Kimmig R.**
[Hormone replacement therapy in patients after breast cancer]
MMW Fortschr Med. 2008 Oct 23;150(43):32-4.
197. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, **Kimmig R**, Forsting M, Bockisch A, Antoch G.
Breast cancer staging in a single session: whole-body PET/CT mammography.
J Nucl Med. 2008 Aug;49(8):1215-22.
198. Allhorn S, Böing C, Koch AA, **Kimmig R**, Gashaw
TLR3 and TLR4 expression in healthy and diseased human endometrium.
Reprod Biol Endocrinol. 2008 Sep 7;6(1):40.
199. Hauth EA, Jaeger HJ, Lubnau J, Maderwald S, Otterbach F, **Kimmig R**,
Forsting MR-guided vacuum-assisted breast biopsy with a handheld biopsy
system: clinical experience and results in postinterventional MR mammography
after 24 h.
Eur Radiol. 2008;18(1): 168-76
200. E. Petru, C. Benedicic, **R. Kimmig**, C. Marth
Frühes Ovarialkarzinom (FIGO Stadium I-IIA)
Der Onkologe 2008;14:1130-1139
201. Tan S, Hahn S, Benson S, Janssen OE, Dietz T, **Kimmig R**, Hesse-Hussain J,
Mann K, Schedlowski M, Arck PC, Elsenbruch S.
Psychological implications of infertility in women with polycystic ovary
syndrome.
Hum Reprod. 2008 Sep.;23(9):2064-71.
202. Schmidt M. Hoffmann B, Beelen D, Gellhaus A, Winterhager E, **Kimmig R**,
Kasimir-Bauer S.
Detection of circulating trophoblast particles in peripheral maternal blood in
preeclampsia complicated pregnancies.
*Hypertens Pregnancy.*2008;27(2):131-42.
203. Fink D, Lang U, **Kimmig R.**
[Fundamental advances in the adjuvant systemic therapy of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(3):111-2.
204. Kummel S, Heidecke H, Brock B, Denkert C, Hecktor J, Koninger A, Becker I,
Sehouli J, Thomas A, Blohmer JU, Lichtenegger W, **Kimmig R.**
[Imatinib--a possible therapeutic option for cervical carcinoma: results of a
preclinical phase I study]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100.

205. Hauth EA, Hoffmann O, Zadow-Eulerich T, **Kimmig R**, Forsting M.
[Magnetic resonance tomography in the diagnostics of breast implants: a survey]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):76-83.
206. Blohmer JU, **Kimmig R**, Kummel S, Costa SD, Kramer S, Rezai M.
[Intraoperative radiotherapy of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):63-7.
207. Kramer S, Darsow M, Kummel S, **Kimmig R**, Rezai M.
Breast-conserving treatment of breast cancer--oncological and reconstructive aspects.
Gynakol Geburtshilfliche Rundsch. 2008;48(2):56-62.
208. **Kimmig R**, Fink D, Lang U.
[Physical integrity versus oncological safety: synthesis of important aspects in the treatment of breast cancer]
Gynakol Geburtshilfliche Rundsch. 2008;48(2):55.
209. Gashaw I, Stiller S, Böing C, **Kimmig R**, Winterhager E.
Pre-menstrual regulation of the pro-angiogenic factor CYR61 in human endometrium.
Endocrinology. 2008 May;149(5):2261-9.
210. Hauth EA, Jaeger H, Maderwald S, Mühler A, **Kimmig R**, Forsting M.
[Quantitative parametric analysis of contrast-enhanced lesions in dynamic MR mammography.]
Radiologe. 2008 Jun;48(6):593-600.
211. Schmidt M, Dogan C, Birdir C, Callies R, Kuhn U, Gellhaus A, Janetzko A, **Kimmig R**, Kasimir-Bauer S.
Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor.
Clin Chem Lab Med. 2007;45(11):1504-10.
212. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M, Elsenbruch S, **Kimmig R**, Mann K, Janssen OE.
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
Eur J Endocrinol. 2007 Nov;157(5):669-76.
213. Fechner S, Husen B, Thole H, Schmidt M, Gashaw I, **Kimmig R**, Winterhager E, Grummer R.
Expression and regulation of estrogen-converting enzymes in ectopic human endometrial tissue.
Fertil Steril. 2007 Oct;88(4 Suppl):1029-38. 2007 Feb 20.
214. Hauth EA, **Kimmig R**, Forsting M.
[Diagnosis of vulval and vaginal neoplasms with magnetic resonance imaging]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):226-35.
215. Schmidt M, **Kimmig R**.
[Pathophysiology of preeclampsia]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):199-204.

216. Schmidt M, Fink D, Lang U, **Kimmig R**.
[Hypertensive diseases during pregnancy: an interdisciplinary challenge]
Gynakol Geburtshilfliche Rundsch. 2007;47(4):197-8.
217. Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W, **Kimmig R**.
The AA Genotype of the Regulatory BCL2 Promoter Polymorphism (938C>A) Is Associated with a Favorable Outcome in Lymph Node Negative Invasive Breast Cancer Patients.
Clin Cancer Res. 2007 Oct 1;13(19):5790-7.
218. Wimberger P, Heubner M, Otterbach F, Fehm T, **Kimmig R**, Kasimir-Bauer S.
Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
Gynecol Oncol. 2007 Aug 30;
219. Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K, **Kimmig R**, Ostermann H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT.
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
J Clin Oncol. 2007 Sep 20;25(27):4187-93. 2007 Aug 13.
220. **Kimmig R**.
[Vaccination against human papilloma virus. Has cervical cancer been beaten?]
MMW Fortschr Med. 2007 Mar 22;149(12):28-9.
221. Böing C, **Kimmig R**.
[Stage-adapted treatment of cervical carcinoma]
MMW Fortschr Med. 2007 Mar 22;149(12):32-4.
222. Schmidt M, **Kimmig R**, Kasimir-Bauer S, et al.
Determination of serum PLGF by ELISA in normal and preeclamptic pregnancies.
CLINICAL CHEMISTRY 53 (6): A209-A209 D155 Suppl. S JUN 2007
223. Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K, **Kimmig R**, Ostermann H, Hinke A, Ledermann JA.
High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Results of a Phase III Intergroup Trial of the AGO-Ovar/AIO and EBMT.
J Clin Oncol. 2007 Aug 13;
224. Hahn S, Backhaus M, Broecker-Preuss M, Tan S, Dietz T, **Kimmig R**, Schmidt M, Mann K, Janssen OE.
Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism.
Eur J Endocrinol. 2007 Aug;157(2):201-7.
225. Hauth EA, Jaeger HJ, Maderwald S, Muehler A, **Kimmig R**, Forsting M.
Quantitative 2- and 3-dimensional analysis of pharmacokinetic model-derived variables for breast lesions in dynamic, contrast-enhanced MR mammography.
Eur J Radiol. 2007 Jul 18;

226. Boing C, **Kimmig R**.
[Surgical management of endometriosis--an overview]
Gynakol Geburtshilfliche Rundsch. 2007;47(3):124-31.
227. Fink D, Lang U, **Kimmig R**.
[Endometriosis—a frequently underestimated disease]
Gynakol Geburtshilfliche Rundsch. 2007;47(3):111-2.
228. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jager M, Strohhlein MA, Heiss MM, Gottwald T, Lindhofer H, **Kimmig R**.
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Clin Cancer Res. 2007 Jul 1;13(13):3899-905.
229. Lang U, Fink D, **Kimmig R**.
[Multiple pregnancies--Part 2]
Gynakol Geburtshilfliche Rundsch. 2007;47(2):55-6.
230. Wimberger P, Lehmann N, **Kimmig R**, Burges A, Meier W, Du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Gynecol Oncol. 2007 Jul;106(1):69-74. 2007 Mar 29.
231. Matuszczyk A, Petersenn S, Lahner H, Haude M, Veit P, Becker JU, **Kimmig R**, Bockisch A, Mann K.
Leydig cell tumor as a cause of hirsutism in a postmenopausal woman.]
Med Klin (Munich). 2007 Mar 15;102(3):259-62.
232. Kummel S, Rezai M, **Kimmig R**, Schmid P.
Dose-dense chemotherapy for primary breast cancer.
Curr Opin Obstet Gynecol. 2007 Feb;19(1):75-81.
233. Lang U, Fink D, **Kimmig R**.
[Multiple pregnancies]
Gynakol Geburtshilfliche Rundsch. 2007;47(1):1-2
234. C. Altgassen, K. Diedrich, **R. Kimmig**, R. Kreienberg
Endometriumkarzinom
Der Gynäkologe 2007; 40:9-9
235. C. Böing, **R. Kimmig**
Therapieoptionen in der Rezidivsituation des Endometriumkarzinoms
Der Gynäkologe 2007;40:44-48
236. C. Böing, **R. Kimmig**
Adjuvante Therapie des Endometriumkarzinoms
Der Gynäkologe 2007; 40:34-43

237. Hahn S, Kuehnel W, Tan S, Kramer K, Schmidt M, Roesler S, **Kimmig R**, Mann K, Janssen OE.
Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome.
Clin Chem Lab Med. 2007;45(2):202-7.
238. Hahn S, Tan S, Sack S, **Kimmig R**, Quadbeck B, Mann K, Janssen OE.
Prevalence of the metabolic syndrome in german women with polycystic ovary syndrome.
Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):130-5.
239. Hauth EA, Khan K, Wolfgarten B, Betzler A, **Kimmig R**, Forsting M.
[Evaluation of the results after using of the BI-RADS categories in 1,777 clinical mammograms.]
Radiologe. 2007 Jan 31;
240. Otterbach F, Callies R, Frey UH, Schmitz KJ, Wreczycki C, **Kimmig R**, Siffert W, Schmid KW.
The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma.
Breast Cancer Res Treat. 2006 Dec 21;
241. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, **Kimmig R**, Mann K, Janssen OE.
Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome.
Exp Clin Endocrinol Diabetes. 2006 Nov;114(10):577-83.
242. Schmidt M, Fink D, Lang U, **Kimmig R**.
[Hormone replacement therapy: curse or blessing?]
Gynakol Geburtshilfliche Rundsch. 2006;46(4):165
243. Schmidt M, **Kimmig R**.
[The benefits and risks of hormonal replacement therapy--an update]
Gynakol Geburtshilfliche Rundsch. 2006;46(4):166-73.
244. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart G, **Kimmig R**, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Luck HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG.
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
J Clin Oncol. 2006 Oct 10;24(29):4699-707. 2006.
245. Wimberger P., Kasimir-Bauer S, Weck B., **Kimmig R**.
Antikörpertherapien beim Ovarialkarzinom
Frauenarzt (2006); 10; 920 – 923
246. Pfisterer J., du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C., **Kimmig R.**, Wollschlaeger K, Heilmann V, Hilpert F.
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
Ann Oncol. 2006 Oct;17(10):1568-1577.

247. Pfisterer J, Weber B, Reuss A, **Kimmig R**, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stahle A, Jackisch C, Hardy-Bessard AC, Mobus V, Quaas J, Richter B, Schroder W, Geay JF, Luck HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. *J Natl Cancer Inst* (2006); 2;98(15):1036-45
248. Böing C, **Kimmig R**. Fertility-preserving treatment in young women with endometrial cancer. *Gynäkol Geburtsh. Rundsch* (2006);46(1-2):25-33
249. Schmitz KJ, Callies R, Wohlschlaeger J, **Kimmig R**, Otterbach F, Bohr J, Lee HS, Takeda A, Schmid KW, Baba HA. Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. *J Clin Pathol* (2006);59(7):685-91
250. Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, Schedlowski M, van Halteren WB, **Kimmig R**, Janssen OE. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. *Hum Reprod* (2006);21(7):1925-34
251. **Kimmig R**, Fink D, Lang U. Organ preservation, multimodal radical tumor therapy and reduction of therapy-related morbidity--development of diagnostics and therapy of endometrial carcinoma. *Gynäkol Geburtsh. Rundsch* (2006);46(1-2):1-2
252. Fink D, Perucchini D, Lang U, **Kimmig R**. Urinary incontinence and descensus genitalis--the silent sickness. *Gynäkol Geburts. Rundsch* (2006);46(3):77-8
253. Hauth EA, Jaeger H, Maderwald S, Stockamp C, Muhler A, **Kimmig R**, Forsting M. Evaluation of quantitative parametric analysis for characterization of breast lesions in contrast-enhanced MR mammography. *Eur Radiol* (2006);29
254. Hauth EA, Stockamp C, Maderwald S, Muhler A, **Kimmig R**, Jaeger H, Barkhausen J, Forsting M. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography. *Clin Imaging* (2006);30(3):160-5
255. Gellhaus A, Schmidt M, Dunk C, Lye SJ, **Kimmig R**, Winterhager E. Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. *Mol Hum Reprod* (2006);12(6):389-99

256. Elsenbruch S, Benson S, Hahn S, Tan S, Mann K, Pleger K, **Kimmig R**, Janssen OE.
Determinants of emotional distress in women with polycystic ovary syndrome.
Hum Reprod (2006);21(4):1092-9
257. Hauth EA, **Kimmig R**, Forsting M.
Magnetic resonance imaging (MRI) of the pelvis in the diagnosis of cervical carcinoma – review.
Zentralbl Gynäkol (2006);128(2):60-7
258. Hahn S, Bering van Halteren W, Roesler S, Schmidt M, **Kimmig R**, Tan S, Mann K, Janssen OE.
The combination of increased ovarian volume and follicle number is associated with more severe hyperandrogenism in German women with polycystic ovary syndrome.
Exp Clin Endocrinol Diabetes (2006);114(4):175-81
259. Hauth EA, Reiter K., **Kimmig R.**, Forsting M.
Die Magnetresonanztomographie (MRT)-gesteuerte Mamma-Vakuumbiopsie mit dem Vacora®-System.
RöFo (2006); S1 178, VO 322.7
260. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, **Kimmig R**, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA.
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Mol Immunol (2006);43(8):1129-43
261. Hauth E, Libera H, **Kimmig R**, Forsting M.
MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy.
Röfo (2006);178(3):316-23
262. Hahn S, Haselhorst U, Quadbeck B, Tan S, **Kimmig R**, Mann K, Janssen OE.
Decreased soluble leptin receptor levels in women with polycystic ovary syndrome.
Eur J Endocrinol (2006);154(2):287-94
263. du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, **Kimmig R**, Pujade-Lauraine E; Arbeitsgemeinschaft Gynaekologische Onkologie; Ovarian Cancer Study Group; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
J Clin Oncol (2006);1;24(7):1127-35

264. Wimberger P, Lehmann N, **Kimmig R**, Burges A, Meier W, Hoppenau B, du Bois A; AGO-OVAR.
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Gynecol Oncol (2006);100(2):300-7
265. Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Hasenburg A, Jager W, **Kimmig R**, Kiechle M, Kommos F, Kreienberg R, Kuhn W, Luck HJ, Meier W, Munstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I, Schroder W, Sehouli J, Tanner B, Wagner U, Weis J.
Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO.
Zentralbl Gynäkol (2006);128(1):11-7
266. Schmitz KJ, Grabellus F, Callies R, Wohlschlaeger J, Otterbach F, **Kimmig R**, Levkau B, Schmid KW, Baba HA.
Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.
Virchows Arch (2006);448(1):16-23
267. du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, **Kimmig R**, Elser G.
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
Ann Oncol (2006);17(1):93-6
268. **Kimmig R**, Wimberger P.
Antikörpertherapien beim Ovarialkarzinom.
ArzneimForsch DrugRes (2005);55 (11):22-3
269. Hauth EA, Reiter K, Hoffmann O, Otterbach F, **Kimmig R**, Forsting M.
MR-guided vacuum assisted breast biopsy.
Zentralbl Gynäkol (2005);127(6):400-6
270. Hauth EA, Wolfgarten B, **Kimmig R**, Forsting M.
MR imaging of the pelvis in characterization of adnexal masses
Zentralbl Gynäkol (2005);127(6):373-9
271. Seeger D, Truong ST, **Kimmig R**.
Spontaneous delivery following tension-free vaginal tape procedure.
Int Urogynecol J Pelvic Floor Dysfunct (2005) 28:1-3
272. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, **Kimmig R**, Benson S, Balamitsa E, Elsenbruch S.
Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome.
Eur J Endocrinol (2005);153(6):853-60
273. Wimberger P, **Kimmig R**.
Surgical treatment of ovarian cancer
MMW Fortschr Med (2005); 27;147(43):31-3

274. **Kimmig R.**
Treatment of ovarian cancer-an update.
MMW Fortschr Med (2005);27;147(43):25-6
275. Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, **Kimmig R**, Forsting M.
Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer.
Eur J Radiol (2005);56(2):263-8
276. Anthuber S, Hepp H, Fink D, **Kimmig R**, Lang U.
Contraception in young adolescents
Gynäkol Geburtsh. Rundsch (2005);45(4):223-4
277. Fink D, **Kimmig R**, Winter R.
Therapy of breast cancer-change from radical to quality-controlled individualized treatment.
Gynäkol Geburtsh. Rundsch (2005);45(3):125-6
278. Heiss MM, Ströhlein MA, Jager M, **Kimmig R**, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H.
Immunotherapy of malignant ascites with trifunctional antibodies.
Int J Cancer (2005); 10;117(3):435-43
279. Winter R, **Kimmig R**, Fink D.
Obstetric/Prenatal ultrasound: blessing or burden?
Gynäkol Geburtsh. Rundsch (2005);45(2):60-1
280. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, **Kimmig R**, Baeuerle PA.
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Cancer Res (2005); 1;65(7):2882-9
281. Hauth EA, Stattaus J, **Kimmig R**, Schmidt M, Forsting M.
Magnetic resonance imaging (MRI) of the pelvis in diagnosing endometriosis.
Zentralbl Gynäkol (2005);127(2):76-82
282. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, **Kimmig R**, Schmid KW, Baba HA.
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
Breast Cancer Res (2005);7(2):R194-203
283. Grabellus F, Worm K, Willruth A, Schmitz KJ, Otterbach F, Baba HA, **Kimmig R**, Metz KA.
ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual.
Breast (2005);14(1):71-4
284. Anthuber S, Hepp H, Fink D, **Kimmig R**, Lang U.
Contraception in young adolescents
Gynäkol Geburtsh. Rundsch (2005);45(4):223-4

285. Kagan KO, Schmidt M, Kuhn U, **Kimmig R**.
Ventricular outflow obstruction, valve aplasia, bradyarrhythmia, pulmonary hypoplasia and non-immune fetal hydrops because of a large rhabdomyoma in a case of unknown tuberous sclerosis: a prenatal diagnosed cardiac rhabdomyoma with multiple symptoms.
BJOG (2004);111(12):1478-80
286. Hauth EA, Antoch G, Ruehm SG, Boing C, **Kimmig R**, Forsting M.
Value of pelvic MRI in the preoperative diagnosis of endometriosis.
Rofo (2004);176(9):1265-70
287. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O, Grabellus F, **Kimmig R**, Schmid KW, Baba HA.
Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.
Mod Pathol (2004);17(1):15-21
288. Kasimir-Bauer S, Otterbach F, Oberhoff C, Schmid KW, **Kimmig R**, Seeber S.
Rare expression of target antigens for immunotherapy on disseminated tumor cells in breast cancer patients without overt metastases.
Int J Mol Med (2003);12(6):969-75
289. Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, Baeuerle PA, **Kimmig R**.
Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.
J Cancer Res Clin Oncol (2003);129(6):341-8
290. Oduncu FS, **Kimmig R**, Hepp H, Emmerich B.
Cancer in pregnancy: maternal-fetal conflict.
J Cancer Res Clin Oncol (2003);129(3):133-46
291. Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle PA, **Kimmig R**.
Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Int J Cancer (2003);10;105(2):241-8
292. **R. Kimmig** T. Strowitzki
Erkrankungen der Ovarien
Der Gynäkologe 2003 961-973
293. Wimberger P, Hillemanns P, Kapsner T, Hepp H, **Kimmig R**.
Evaluation of prognostic factors following flow-cytometric DNA analysis after cytokeratin labelling: II. Cervical and endometrial cancer.
Anal Cell Pathol (2002);24(4-5):147-58
294. Wimberger P, Hillemanns P, Kapsner T, Hepp H, **Kimmig R**.
Evaluation of prognostic factors following flow-cytometric DNA analysis after cytokeratin labelling: I. Breast cancer.
Anal Cell Pathol (2002);24(4-5):135-45
295. C. Oberhoff, **R. Kimmig**, O. Kagan
Mammkarzinom in der Schwangerschaft
Der Onkologe 2002;8:1309-1317

296. F.S. Oduncu, **R. Kimmig**, B. Emmerich
Krebs und Gravidität
Der Onkologe 2002;8:1, 559-562
297. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, **Kimmig R**, Rehbock J, Hölzel D.
Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.
Eur J Cancer (2002);38(18):2435-45
298. Otto T, Suhr J, Krege S, Goebell PJ, Wishahi M, Bier UW, **Kimmig R**, Rübben, Surgical treatment of disseminated peritoneal metastases from urological cancer: results from a prospective study.
BJU Int (2002);90(9):823-7
299. A. Willruth, **R. Kimmig**
Standards in der perioperativen Ernährungs- und Infusionstherapie
Der Gynäkologe 2002;35:1225-1230
300. Hasbargen U, Summerer-Moustaki M, Hillemanns P, Scheidler J, **Kimmig R**, Hepp H.
Uterine dehiscence in a nullipara, diagnosed by MRI, following use of unipolar electrocautery during laparoscopic myomectomy: Case report.
Hum Reprod (2002);17(8):2180-2
301. Hasbargen U, Strauss A, Summerer-Moustaki M, Baretton G, Roth U, **Kimmig R**, Hepp H.
Myomectomy as a pregnancy-preserving option in the carefully selected patient.
Fetal Diagn Ther (2002);17(2):101-3
302. **Kimmig R**, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H.
Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Gynecol Oncol (2002);84(1):21-31
303. Peiro G, Diebold J, Baretton GB, **Kimmig R**, Löhrs U.
Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome.
Int J Gynecol Pathol (2001);20(4):359-67
304. Peiro G, Diebold J, Mayr D, Baretton GB, **Kimmig R**, Schmidt M, Lohrs U.
Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in endometrial carcinoma.
Mod Pathol (2001);14(8):777-83
305. du Bois A, Luck HJ, Pfisterer J, Schroeder W, Blohmer JU, **Kimmig R**, Moebus V, Quaas J.
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group.
Ann Oncol (2001);12(8):1115-20

306. W. Meier, **R. Kimmig**, W. Lichtenegger
Die operative Therapie des Rezidivs
Der Gynäkologe 2001;34:1024-1028
307. **Kimmig R**, Wimberger P, Kapsner T, Hillemanns P.
Flow cytometric DNA analysis using cytokeratin labeling for identification of tumor cells in carcinomas of the breast and the female genital tract.
Anal Cell Pathol (2001);22(3):165-78
308. Konecny G, Untch M, Pihan A, **Kimmig R**, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M.
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Clin Cancer Res (2001);7(6):1743-9
309. Hillemanns P, **Kimmig R**, Hepp H.
Hormonale Substitution und extragenitale Neoplasien.
Gynäkologe (2000);33:416-22
310. **Kimmig R**, Hillemanns P, Hepp H.
Tibolon – eine Alternative zur Östrogensubstitution?
Gynäkologe (2000);33:408-15
311. K. Diedrich, O. Ortmann, **R. Kimmig**, H. Hepp
Neue Aspekte der Hormonsubstitution
Gynäkologe (2000);33:383-384
312. Sevelde P, **Kimmig R**.
Schwangerschaftsbedingte Trophoblasterkrankungen. In: Lehrbuch der Onkologie. Hrsg. W. Hiddemann, München; Huber, Wien; Bartram, Heidelberg Springer Verlag (2000)
313. **Kimmig R**, Seehaus D, Hillemanns P, Hepp H.
Hormonelle Substitution und Mammakarzinom. In: Diagnostik und Therapie des Mammakarzinoms. State of the art. Untch M, Konecny G, Sittek H, Kessler M, Reiser M, Hepp H (eds.) 2 edn. (überarbeitete Auflage)
W Zuckschwerdt Verlag München Bern Wien New York (2000).
314. Hillemanns P, Dannecker C, **Kimmig R**, Hasbargen U.
Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy.
Acta Obstet Gynecol Scand (2000);79(7):543-7
315. Hillemanns P, **Kimmig R**, Dannecker C, Noorzai T, Diebold J, Thaler CJ, Hepp H.
LEEP versus cold knife conization for treatment of cervical intraepithelial neoplasias
Zentralbl Gynäkol (2000);122(1):35-42
316. **Kimmig R**, Hillemanns P, Burges A, Hepp H.
Fertilitätserhaltung bei gynäkologischen Malignomen – Risikobezogene Therapiestrategien. In: Neuerungen in der Onkologie. Utopie und Wirklichkeit? Hrsg. Clemm Ch, Gutschow K.
W Zuckschwerdt Verlag ISBN 3-88603-669-3, (1999): S. 64-74

- 317. Kimmig R.**
Durchflußzytometrische DNA-Analyse solider gynäkologischer Tumoren nach Zytokeratinmarkierung zur Detektion der Tumorzellen.
Habitationsschrift Ludwig-Maximilians-Universität München 1999
- 318.** Hillemanns P, **Kimmig R**, Huttemann U, Dannecker C, Thaler CJ.
Screening for cervical neoplasia by self-assessment for human papillomavirus DNA.
Lancet (1999);4;354(9194):1970
- 319.** Hillemanns P, Korell M, Schmitt-Sody M, Baumgartner R, Beyer W, **Kimmig R**, Untch M, Hepp H.
Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid.
Int J Cancer (1999);31;81(1):34-8
- 320. Kimmig R.**
5. Recurrent cervical carcinoma – an invited comment.
Hungar J Gynecol Oncol (1998)
- 321. Kimmig R**, Seehaus D, Hillemanns P, Hepp H.
Hormonelle Substitution und Mammakarzinom. In: Diagnostik und Therapie des Mammakarzinoms. State of the art. Untch M, Konecny G, Sittek H, Kessler M, Reiser M, Hepp H (eds).
W Zuckschwerdt Verlag München Bern Wien New York (1998): S. 77-82
- 322. Kimmig R**, Strowitzki T, Hepp H.
Moderately differentiated endometrial carcinoma cured by conservative treatment. Letter to the Editor.
Int J Gynecol Cancer (1998);8:511-2
- 323.** Singer GA, Strowitzki T, Rettig I, **Kimmig R**.
Flow cytometric detection and binding studies of human endometrial stromal cell epidermal growth factor receptor in monolayer culture: influence of progesterone.
Mol Hum Reprod (1998);4(6):577-83
- 324.** Loscar M, Schelling G, Haller M, Polasek J, Stoll C, Kreimeier U, Finsterer U, Steitz HO, Baumeister R, **Kimmig R**, Grabein B, Briegel J.
Group A streptococcal toxic shock syndrome with severe necrotizing fasciitis following hysterectomy--a case report.
Intensive Care Med (1998);24(2):190-3
- 325.** Pfeiffer D, **Kimmig R**, Herrmann J, Ruge M, Fisseler-Eckhoff A, Scheidel P, Jensen A, Schatz H, Pfeiffer A.
Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus.
Int J Cancer (1998);20;79(1):49-55
- 326.** Scheidler J, Heuck AF, Steinborn M, **Kimmig R**, Reiser MF.
Parametrial invasion in cervical carcinoma: evaluation of detection at MR imaging with fat suppression.
Radiology (1998);206(1):125-9

327. **Kimmig R**, Hillemanns P, Hepp H.
Die diagnostische Hysteroskopie – ein neuer Standard.
Gynäkologe (1997);30:384-91
328. **Kimmig R**, Pfeiffer D, Landsmann H, Hepp H.
Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: evidence for down-regulation in cervical cancer.
Int J Cancer (1997); 22;74(4):365-73
329. Pfeiffer D, Spranger J, Al-Deiri M, **Kimmig R**, Fisseler-Eckhoff A, Scheidel P, Schatz H, Jensen A, Pfeiffer A.
mRNA expression of ligands of the epidermal-growth-factor-receptor in the uterus.
Int J Cancer (1997); 7;72(4):581-6
330. Hillemanns P, **Kimmig R**, Arnholdt H.
Conservative management of Sertoli-Leydig cell tumor of the ovary.
Acta Obstet Gynecol Scand (1997);76(6):604-7
331. Scheidler J, Heuck A, Wencke K, **Kimmig R**, Muller-Lisse U, Reiser M.
Parametrial infiltration of cervix carcinoma: diagnostic value of contrast-enhanced fat-suppressed T1-weighted SE sequences at 1.5 tesla.
Röfo (1997);166(4):312-6
332. Heuck A, Scheidler J, **Kimmig R**, Muller-Lisse U, Steinborn M, Helmberger T, Reiser M.
Lymph node staging in cervix carcinomas: the results of high-resolution magnetic resonance tomography (MRT) with a phased-array body coil.
Röfo (1997);166(3):210-4
333. Hillemanns P, Thaler C, **Kimmig R**.
Epidemiology and diagnosis of cervical intraepithelial neoplasia--is the present concept of screening and diagnosis still current?
Gynäkol Geburtsh. Rundsch (1997);37(4):179-91
334. Scheidler J, Heuck AF, Bruening R, Kohz P, **Kimmig R**, Stehling MK, Reiser MF.
Magnetic resonance imaging of the female pelvis. New circularly polarized body array coil versus standard body coil.
Invest Radiol (1997);32(1):1-6
335. **Kimmig R**.
Diagnostik Gonadeninsuffizienz und Therapie Östogene in: Empfehlungen zu Prävention, Diagnostik und Therapie der Osteoporose. (Hrsg: E. Senn, B. Busch)
Manual der Arbeitsgruppe Osteoporose der Ludwig-Maximilians-Universität München, 2. Auflage (1996)
336. Romisch M, Meier W, **Kimmig R**, Hepp H.
13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva.
Geburtshilfe Frauenheilkunde (1996);56(10):520-4

337. Regidor PA, Schindler AE, Buhler K, Gerhard I, **Kimmig R**, Meinen K, Hoffmann G, Lubben G, Kienle E.
Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot).
Zentralbl Gynäkol (1996);118(5):283-90
338. Gutschow K, **Kimmig R**.
Hormonsubstitution und gynäkologische Malignome, Krebsrisiko – Lebensqualität.
Krebs (1995);14:49-54
339. **Kimmig R**.
Hysteroskopische Chirurgie.
Arch Gynecol Obstet (1995);257:21-9
340. **Kimmig R**.
Cabergolin – Ein neuer hypophysärer Dopamingonist.
Arzneimittelther (1995);13: 222-3
341. Kirschstein M, Untch M, Korell M, Hillemanns P, **Kimmig R**.
Durchflußzytometrische Untersuchungen zur Wirkungen von delta-Aminolaevulinsäure (ALA) und Photodynamische Lasertherapie (PDT) auf den Zellzyklus von Zervixkarzinomzellen.
Laser in der Medizin, Springer Heidelberg (1995), 254-8
342. **Kimmig R**, Knitza R (Hrsg.), Hepp F, Klocke G, Wagner C.
Gynäkologie pur, das Skript
Börm Bruckheimer Verlag GmbH, Grünwald (1995)
343. **Kimmig R**, Knitza R (Hrsg.), Hepp F, Klocke G, Wagner C.
Gynäkologie pur, die Karteikarten
Börm Bruckmeier Verlag GmbH, Grünwald (1995)
344. **Kimmig R**, Seehaus D, Scheidel P, Hepp H.
Hormonelle Substitution und orale Kontrazeption. Risiko der Induktion oder Reaktivierung gynäkologischer Malignome.
Gynäkol Geburtsh. Rundsch (1995);35:72-8
345. **Kimmig R**, Landsmann H, Fileki M, Spelsberg H, Untch M, Kapsner T.
DNS-Zellzyklusanalyse beim Mammakarzinom nach Zytokeratinmarkierung zur Identifizierung der Tumorzellen. Buchbeitrag in: Aktuelle Onkologie Band 86, Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie (Kreienberg R, Grill HJ, Möbus V, Koldovsky U; Hrsg.).
Zuckschwerdt Verlag München Bern Wien New York (1995), S. 251-9
346. **Kimmig R**, Strowitzki T, Muller-Hocker J, Kurzl R, Korell M, Hepp H.
Conservative treatment of endometrial cancer permitting subsequent triplet pregnancy.
Gynecol Oncol (1995);58(2):255-7
347. Gerber B, Krause A, **Kimmig R**.
Immunohistologic tumor cell detection in lymph nodes in node negative breast cancer: correlation with "established" and "recent" prognostic factors.
Gynäkol Geburtsh. Rundsch (1995);35 Suppl 1:32-5

- 348. Kimmig R.**
Hysteroscopic surgery.
Arch Gynecol Obstet (1995);257(1-4):21-9
- 349.** Luppä P, Müller B, Jacob K, **Kimmig R**, Strowitzki T, Hoss C, Weber MM, Engelhardt D, Lobo RA.
Variations of steroid hormone metabolites in serum and urine in polycystic ovary syndrome after nafarelin stimulation: evidence for an altered corticoid excretion.
J Clin Endocrinol Metab (1995);80(1):280-8
- 350. Kimmig R**, Seehaus D, Scheidel P, Hepp H.
Hormonal replacement therapy and oral contraception. Risk of induction or reactivation of gynecologic malignancies.
Gynäkol Geburtshilfliche Rundsch (1995);35(2):72-8
- 351. Kimmig R**, Kürzl R, Höß C, Landsmann H.
(Redaktion) für die Projektgruppe Zervix- und Endometriumkarzinom des Tumorzentrums München. Manual: Zervixkarzinom: Empfehlungen zur Diagnostik, Therapie und Nachsorge, Tumorzentrum München (1994)
- 352. Kimmig R**, Klocke G und Hepp H.
Erfordernisse der präoperativen Diagnostik bei gynäkologischen Erkrankungen im kleinen Becken.
Radiologie (1994);34:346-50
- 353. Kimmig R**, Kapsner T, Spelsberg H, Untch M, Hepp H.
DNA cell-cycle analysis of cervical cancer by flow cytometry using simultaneous cytokeratin labeling for identification of tumor cells.
J Cancer Res Clin Oncol (1995);121(2):107-14
- 354. Kimmig R**, Seehaus D, Scheidel P, Hepp H.
Krebserkrankungen – hormonelle Substitution – orale Kontrazeption.
Kongresszeitung 50. Kongreß der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (1994) S. 12-14
- 355. Kimmig R**, Egner D, Hepp H.
Durchflußzytometrische DNS-Analyse maligner epithelialer gynäkologischer Tumoren. In: Tumorimmunologie in der Gynäkologie (Koldovsky U, Kreienberg R, Hrsg.)
Zuckschwerdt Verlag München Bern Wien New York (1994) S. 124-31
- 356.** Kürzl R, **Kimmig R**, Schürmann H.
(Redaktion) für die Projektgruppe Zervix- und Endometriumkarzinom des Tumorzentrums München. Manual: Endometriumkarzinom. Empfehlung zur Diagnostik, Therapie und Nachsorge, Tumorzentrum München (1994).
- 357. Kimmig R**, Spelsberg H, Kapsner T, Untch M, Hepp H.
Flow cytometric DNA analysis of breast cancer by two colour method using cytokeratin labeling for identification of tumour cells.
Anal Cell Pathol (1994);7(3):205-15
- 358.** Schindler AE, Bühler K, Gerhard I, Wiedemann R, **Kimmig R**, Schüssler B, Kranzfelder D, Mall-Häfelì M, Meinen K, Mancarella D, Hofmann G.
Behandlung der Endometriose mit dem GnRH-Agonisten Leuprorelinacetat Depot (Enantone Gyn Monats-Depot): Eine multizentrische Studie.
Zentralbl Gynäkol (1994);116:679-86

359. Webster J, Piscitelli G, Polli A, Ferari CI, Ismail I. Scanlon MF for the Cabergoline Comparative Study Group*, *...R. Kimmig and O.A. Muller, Munich, Germany; Cabergoline versus bromocriptine in the treatment of hyperprolactinemic amenorrhea. *New Engl J Med* (1994);331:904-09
360. **Kimmig R**, Klocke G, Hepp H. Requirements in preoperative diagnosis of gynecologic diseases of the pelvis *Radiologe* (1994);34(7):346-50
361. Schindler AE, Buhler K, Gerhard I, Wiedemann R, **Kimmig R**, Schussler B, Kranzfelder D, Mall-Hafeli M, Meinen K, Mancarella D, et al. Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study. *Zentralbl Gynäkol* (1994);116(12):679-86
362. **Kimmig R**, Ratzel R. Eigenblutspende in Gynäkologie und Geburtshilfe. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. *Der Frauenarzt* (1993);34:606-7
363. **Kimmig R**. Metergolin – ein hypophysärer Dopaminagonist. *Arzneimittelther* (1993);11:143-4
364. **Kimmig R**. Nafarelin – GnRH-Agonist zur Behandlung der Endometriose. *Arzneimittelther* (1993);11:145-7
365. **Kimmig R**, Pfeiffer D, Pfeiffer A, Hepp H. Bestimmung des EGF-Rezeptors zur Prognoseeinschätzung des Zervixkarzinoms. *Arch Gynecol Obstet* (1993);254:1028-30
366. **Kimmig R**, Hasbargen U, Hepp H. Hysteroscopic staging of endometrial cancer. Comment on the contribution by R. Schild, Th. Kutter *Geburtshilfe und Frauenheilkunde* (1993);53(6):433-4
367. Untch M, Nestle-Kramling C, Konecny G, Harbeck N, Funke I, **Kimmig R**, Hepp H. Prognostic value of tumor cells in bone marrow in breast cancer. *Gynäkol Geburtsh. Rundsch* (1993);33 Suppl 1:308-10
368. **Kimmig R**, Untch M, Pfeiffer D, Egner D, Strowitzki T, Hepp H. Multiparametric flow cytometry determination of the EGF receptor and DNA cell cycle distribution in cervix cancer. *Gynäkol Geburtsh. Rundsch* (1993);33 Suppl 1:283-4
369. Gerhard I, Schindler AE, Buhler K, Winkler U, Meinen K, Mancarella D, Hoffmann G, Schussler B, **Kimmig R**, Kranzfelder D. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. *Clin Ther* (1992);14 Suppl A:3-16

- 370. Kimmig R.**
Standardlagerungen: Buchbeitrag in: Hepp H, Scheidel P, Schüssler B, Gynäkologische Standardoperationen.
Ferdinand Enke, Stuttgart (1991):373-8
- 371.** Gerhard I, Schindler AR, Bühler K, Winkler U, Meinen K, Mancella D, Hoffmann G, Schüssler B, **Kimmig R**, Kranzfelder D.
Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study.
Clin Ther (1991);14 Suppl A:3-16
- 372.** Strowitzki T, Wiedemann R, **Kimmig R**, Hepp H.
Einfluß von EGF, IGF-1 und Wachstumshormon auf endometriale Stromazellen in vitro.
Arch Gynecol Obstet 250: (1991) 1015-1016
- 373. Kimmig R**, Egnér D, Spelsberg H, Untch M, Kapsner Th.
Durchflußzytometrische DNA-Analyse bei Mammakarzinomen: Korrelaton mit klinischen Prognosefaktoren.
Arch Gynecol Obstet (1991);250: 209-210
- 374.** Luppá P, Neumeier D, **Kimmig R**.
Rationelle Labordiagnostik des Hyperandrogenismus der Frau.
Ärztl Lab (1989);35:247-52
- 375.** Pfeiffer DG, Ritz P, **Kimmig R**, Mann K, Scheidel P.
EGF and TGF-beta: effects on growth and on the secretion of beta-HCG in cervical carcinoma cells.
Acta Endo (1989);120 (S):145-146
- 376.** Jochmus-Kudielka I, Schneider A, Braun R, **Kimmig R**, Koldovsky U, Schneweis KE, Seedorf K, Gissmann L.
Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer.
J Natl Cancer Inst (1989);81(22):1698-1704
- 377.** Hartl WH, Jauch KW, **Kimmig R**, Wicklmayr M, Gunther B, Heberer G.
Minor role of ketone bodies in energy metabolism by skeletal muscle tissue during the postoperative course.
Ann Surg (1988);207(1):95-101
- 378. Kimmig R.**
Über die Kurzzeitregulation des Leberstoffwechsels durch Glucagon: Wirkungen auf Glykogenolyse, Glykolyse, Sauerstoffverbrauch und Ketogenese, Kinetiken der direkten und indirekten Glucagoneffekte, Interaktionen der Stoffwechselprozesse im "transient" und im "steady state", untersucht in der isolierten, nichtrezirkulierend perfundierten Rattenleber.
Inauguraldissertation an der Ludwig-Maximilians-Universität München. (1986)
- 379. Kimmig R**, Mauch TJ, Scholz R.
Actions of glucagon on flux rates in perfused rat liver. 2. Relationship between inhibition of glycolysis and stimulation of respiration by glucagon.
Eur J Biochem (1983) 15;136(3):617-20

- 380.** **Kimmig R,** Mauch TJ, Kerzl W, Schwabe U, Scholz R.
Actions of glucagon on flux rates in perfused rat liver. 1. Kinetics of the
inhibitory effect on glycolysis and the stimulatory effect on glycogenolysis.
Eur J Biochem (1983) 15;136(3):609-16